Provider: Thomson Reuters Stock Report
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
MEDRx Co Ltd Files IND Application for Phase III Clinical Trial on ETOREAT
MEDRx Co Ltd announced that it has filed an Investigational New Drug (IND) application to Food and Drug Administration (FDA) for the initiation of phase III clinical trial on ETOREAT, which is an antiphlogistic analgetic adhesive patch. The Company will start the clinical trial in November 2013 if the application is accepted.
Latest Key Developments in Pharmaceuticals
- Adamis Pharmaceuticals Corp announces pricing of public offering shares
- Merrimack Pharmaceuticals Inc announces encouraging clinical data from expanded phase one study of MM-302 for the treatment of advanced her2-positive breast cancer
- Perrigo Co And Elan Corporation plc receive Irish High Court approval for Perrigo's proposed acquisition of Elan
- Torrent Pharmaceuticals Ltd to acquire indian branded formulations business of Elder Pharmaceuticals Ltd
- Share this
- Digg this